Evidence map›Paper›PMID 26432900›Full record

ArticleJournal of leukocyte biology2016

Cytokine overproduction and crosslinker hypersensitivity are unlinked in Fanconi anemia macrophages.

Michael R Garbati, Laura E Hays, R Keaney Rathbun, Nathaniel Jillette, Kathy Chin, Muhsen Al-Dhalimy, Anupriya Agarwal, Amy E Hanlon Newell, Susan B Olson, Grover C Bagby

Open access · bronzeAbstract read
In one paragraph

Article in Journal of leukocyte biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Michael R Garbati*Northwest Veterans Affairs Cancer Research Center, Portland, Oregon, USA; Oregon Health & Science University, Portland, Oregon, USA; and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Laura E Hays*Northwest Veterans Affairs Cancer Research Center, Portland, Oregon, USA; Oregon Health & Science University, Portland, Oregon, USA; and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
R Keaney Rathbun*Northwest Veterans Affairs Cancer Research Center, Portland, Oregon, USA; Oregon Health & Science University, Portland, Oregon, USA; and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Nathaniel Jillette*Northwest Veterans Affairs Cancer Research Center, Portland, Oregon, USA; Oregon Health & Science University, Portland, Oregon, USA; and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Kathy Chin*Northwest Veterans Affairs Cancer Research Center, Portland, Oregon, USA; Oregon Health & Science University, Portland, Oregon, USA; and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Muhsen Al-Dhalimy*Northwest Veterans Affairs Cancer Research Center, Portland, Oregon, USA; Oregon Health & Science University, Portland, Oregon, USA; and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Anupriya Agarwal*Northwest Veterans Affairs Cancer Research Center, Portland, Oregon, USA; Oregon Health & Science University, Portland, Oregon, USA; and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Amy E Hanlon Newell*Northwest Veterans Affairs Cancer Research Center, Portland, Oregon, USA; Oregon Health & Science University, Portland, Oregon, USA; and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Susan B Olson*Northwest Veterans Affairs Cancer Research Center, Portland, Oregon, USA; Oregon Health & Science University, Portland, Oregon, USA; and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Grover C Bagby*Northwest Veterans Affairs Cancer Research Center, Portland, Oregon, USA; Oregon Health & Science University, Portland, Oregon, USA; and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA grover@ohsu.edu.
Oregon Health & Science University · USCancer Research Center · USPortland VA Medical Center · USOHSU Knight Cancer Institute

Funding

Xenograft CoreP01HL048546 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI FLEMING, WILLIAM H · 1994 to 2020
$36.4M
NHLBI NIH HHS P01 HL048546
6 · The paper itself

Abstract

The Fanconi anemia proteins participate in a canonical pathway that repairs cross-linking agent-induced DNA damage. Cells with inactivated Fanconi anemia genes are universally hypersensitive to such agents. Fanconi anemia-deficient hematopoietic stem cells are also hypersensitive to inflammatory cytokines, and, as importantly, Fanconi anemia macrophages overproduce such cytokines in response to TLR4 and TLR7/8 agonists. We questioned whether TLR-induced DNA damage is the primary cause of aberrantly regulated cytokine production in Fanconi anemia macrophages by quantifying TLR agonist-induced TNF-α production, DNA strand breaks, crosslinker-induced chromosomal breakage, and Fanconi anemia core complex function in Fanconi anemia complementation group C-deficient human and murine macrophages. Although both M1 and M2 polarized Fanconi anemia cells were predictably hypersensitive to mitomycin C, only M1 macrophages overproduced TNF-α in response to TLR-activating signals. DNA damaging agents alone did not induce TNF-α production in the absence of TLR agonists in wild-type or Fanconi anemia macrophages, and mitomycin C did not enhance TLR responses in either normal or Fanconi anemia cells. TLR4 and TLR7/8 activation induced cytokine overproduction in Fanconi anemia macrophages. Also, although TLR4 activation was associated with induced double strand breaks, TLR7/8 activation was not. That DNA strand breaks and chromosome breaks are neither necessary nor sufficient to account for the overproduction of inflammatory cytokines by Fanconi anemia cells suggests that noncanonical anti-inflammatory functions of Fanconi anemia complementation group C contribute to the aberrant macrophage phenotype and suggests that suppression of macrophage/TLR hyperreactivity might prevent cytokine-induced stem cell attrition in Fanconi anemia.

Indexed as

AnimalsCell PolarityCells, CulturedCross-Linking ReagentsDNA DamageFanconi AnemiaFanconi Anemia Complementation Group C ProteinHistonesHumansImidazolesMacrophagesMiceMitomycinReactive Oxygen SpeciesToll-Like ReceptorsTumor Necrosis Factor-alphaCross-Linking ReagentsFancc protein, mouseFanconi Anemia Complementation Group C ProteinH2AX protein, humanHistonesImidazolesMitomycinReactive Oxygen SpeciesresiquimodToll-Like ReceptorsTumor Necrosis Factor-alphaDNA damageTLRTNF-α

Identifiers

PMID26432900
PMCPMC6608044
OpenAlexW2263130037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.